Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) Cost of Revenue (2019 - 2025)

Bioadaptives' Cost of Revenue history spans 7 years, with the latest figure at $781.0 for Q3 2025.

  • For Q3 2025, Cost of Revenue changed N/A year-over-year to $781.0; the TTM value through Sep 2025 reached $2937.0, down 77.65%, while the annual FY2024 figure was $8639.0, 51.32% down from the prior year.
  • Cost of Revenue for Q3 2025 was $781.0 at Bioadaptives, down from $2156.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $10999.0 in Q3 2023 and bottomed at $246.0 in Q2 2024.
  • The 5-year median for Cost of Revenue is $2198.0 (2021), against an average of $3065.2.
  • The largest annual shift saw Cost of Revenue plummeted 71.02% in 2024 before it surged 776.42% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $2709.0 in 2021, then grew by 9.04% to $2954.0 in 2022, then soared by 52.4% to $4502.0 in 2023, then tumbled by 94.54% to $246.0 in 2024, then skyrocketed by 217.48% to $781.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Cost of Revenue are $781.0 (Q3 2025), $2156.0 (Q2 2025), and $246.0 (Q2 2024).